



Aspira Pathlab & Diagnostics Limited

Regd. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400 086
CIN : L85100MH1973PLC289209

Date: November 11, 2023

To,
Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788

Security ID: ASPIRA

Sub: Outcome of Board Meeting- Approval of the Unaudited Financial Results alongwith the Limited Review Report for the quarter ended September 30, 2023.

Dear Sir/Madam,

Pursuant to the Regulation 30 read with Schedule III and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("SEBI LODR"), please find attached herewith the Unaudited Financial Results along with Limited Review Report for the quarter & half year ended September 30, 2023 duly reviewed and approved by the Audit Committee and Board of Directors respectively at their meeting held on today i.e. November 11, 2023.

Kindly note that Board Meeting had commenced at 12.00 P.M (IST) and concluded at 01.30 P.M.(IST)

Request you to take the same on your record.

Thanking you.

Yours Faithfully,

For **Aspira Pathlab & Diagnostics Limited**

Krupali Shah
Company Secretary & Compliance Officer

Independent Auditor's Review Report on unaudited financial results of Aspira Pathlab & Diagnostics Limited for the quarter and half year ended September 30, 2023 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

Review Report

To The Board of Directors of
Aspira Pathlab & Diagnostics Limited

We have reviewed the accompanying statement of **Unaudited Financial Results** of **Aspira Pathlab & Diagnostics Limited** ("the Company") for the quarter and half year ended September 30, 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR Regulation") including relevant circulars issued by the SEBI from time to time.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P Khetan & Co
Chartered Accountant
Firm Reg. No. 327386E



Pankaj Kumar Khetan
Partner

Membership No.- 066080
UDIN: 23066080BGSASK8131



Place- Mumbai
Date- 11.11.2023

ASPIRA PATHLAB & DIAGNOSTICS LIMITED

(CIN : L85100MH1973PLC289209)

Reg. Office: Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Tel No. 022-71975755, Email: support@aspiradiagnostics.com, Website: www.aspiradiagnostics.com

Statement of Assets & Liabilities as at 30 September 2023

(Rupees in Lakhs)

Particulars	As at 30 September 2023 (un-audited)	As at 31 March 2023 (Audited)
A ASSETS		
Non-current assets		
Property, plant and equipment	300.64	320.21
Right of Use Assets	280.56	211.09
Goodwill	265.18	265.18
Other Intangible assets	1.57	4.40
Financial Assets		
(i) Loans and advances	113.85	312.57
(ii) Others	39.79	35.09
Total non-current assets	1,095.59	1,148.53
Current Assets		
Inventories	45.51	39.89
Financial Assets		
(i) Trade Receivables	195.95	233.85
(ii) Cash and Cash Equivalents	47.23	56.66
(iii) Bank balances other than (i) above	164.79	178.28
(iv) Others financial assets	7.42	2.28
Current tax assets (net)	30.56	58.63
Other Current Assets	14.49	16.05
Total Current Assets	506.96	585.64
Total Assets	1,602.54	1,734.17
B EQUITY AND LIABILITIES		
EQUITY		
Equity share Capital	1,029.30	1,029.30
Other equity	103.05	245.74
Total Equity	1,132.35	1,275.04
LIABILITIES		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	101.95	96.18
(ii) Lease liabilities	133.41	167.69
Provisions	40.39	36.79
Total non-current liabilities	275.75	300.66
Current liabilities		
Financial liabilities		
(i) Borrowings		
(ii) Lease liabilities	72.05	67.48
(iii) Trade payables		
Total outstanding dues of micro and small enterprises		
Total outstanding dues of other than micro and small enterprises	57.92	34.50
(iv) Other financial liabilities	51.61	44.23
Other current liabilities	10.59	10.58
Provisions	2.28	1.68
Total current liabilities	194.45	158.48
Total Liabilities	470.19	459.14
Total Equity and Liabilities	1,602.54	1,734.18

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Vange
Nikunj Vange
Executive Director
DIN: 08489442
Place: Mumbai
Date: 11.11.2023



For Identification only

ASPIRA PATHLAB & DIAGNOSTICS LIMITED
(CIN LB5100MH1973PLC289 ID9)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086
Tel No. 022-71975756, Email : support@aspiradiagnostics.com, Website : www.aspiradiagnostics.com
Statement of Unaudited Financial Results for the quarter and half year ended 30th September, 2023

Particulars	(Rupees in Lakhs)					
	For the Quarter ended		For the Half Year ended			For the Year ended
	30-Sep-23 (Unaudited)	30-Jun-23 (Unaudited)	30-Sep-22 (Unaudited)	30-Sep-23 (Unaudited)	30-Sep-22 (Unaudited)	31-Mar-23 (Audited)
1. Income						
(a) Revenue from Operations	332.15	260.38	370.88	592.53	667.58	1,445.69
(b) Other Income	14.44	10.03	6.69	24.47	13.18	32.09
Total Income	346.59	270.41	377.57	617.00	680.76	1,477.78
2. Expenses						
(a) Cost of Materials consumed	66.79	51.24	69.15	118.02	122.56	249.71
(b) Laboratory Testing Charges	19.31	12.57	14.02	31.88	24.86	51.12
(c) Employee benefits expense	163.02	131.04	135.56	294.06	267.37	559.28
(d) Finance Costs	9.66	9.78	10.90	19.44	21.81	41.72
(e) Depreciation and amortisation expense	39.00	39.15	40.03	78.15	81.94	158.56
(f) Other expenses	119.90	98.24	106.41	218.13	189.24	426.25
Total Expenses	417.67	342.01	376.06	759.68	707.77	1,486.65
3. Profit / (Loss) before exceptional items and tax (1-2)	(71.09)	(71.60)	1.51	(142.68)	(27.01)	(8.87)
4. Exceptional Items	-	-	-	-	-	-
5. Profit / (Loss) before tax (3+4)	(71.09)	(71.60)	1.51	(142.68)	(27.01)	(8.87)
6. Tax Expenses	-	-	-	-	-	-
7. Profit / (Loss) after tax (5-6)	(71.09)	(71.60)	1.51	(142.68)	(27.01)	(8.87)
8. Other Comprehensive Income (net of tax)	-	-	-	-	-	4.96
9. Total Comprehensive Income / (Loss) (7+8)	(71.09)	(71.60)	1.51	(142.68)	(27.01)	(3.91)
10. Paid up Equity share capital (face value of Rs.10 each)	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30	1,029.30
11. Other Equity	-	-	-	-	-	245.74
12. Earning per share (in Rupees)						
(a) Basic	(0.69)	(0.70)	0.01	(1.39)	(0.26)	(0.09)
(b) Diluted	(0.69)	(0.70)	0.01	(1.39)	(0.26)	(0.09)

Notes

- The above unaudited financial results of the Company for the quarter and half year ended September 30, 2023 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 11th November, 2023.
- The above unaudited financial results for the quarter and half year ended September 30, 2023 has been subjected to limited review by statutory auditors of the Company and not subjected to audit. The auditors have expressed an unmodified opinion in the limited review report for the quarter and half year ended September 30, 2023.
- These unaudited financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.
- The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') relating to employee benefits during employment and post-employment benefits. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect is yet to be notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact after the Code becomes effective.
- The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Munge
Nikunj Munge
Executive Director
DIN: 08489442
Place : Mumbai
Date : 11.11.2023



ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Statement of Cash flow for the half year ended 30th Sep 2023

(All amounts in Lakhs, unless otherwise stated)

Particulars	For the half year ended 30.09.2023	
	(un-audited)	(un-audited)
A CASH FLOW FROM OPERATING ACTIVITIES		
Profit/(Loss) for the year	(142.69)	(27.01)
Adjustments for:		
Interest income	(22.37)	(13.18)
Finance Costs	19.44	21.81
Depreciation and amortisation expenses	78.15	81.94
Profit on lease termination	1.66	-
Provision for impairment of trade receivables and advances	1.54	(5.00)
Operating profit before working capital changes	(64.26)	58.55
Working capital adjustments:		
(Increase)/Decrease in Trade receivables	35.35	224.73
(Increase)/Decrease in Inventories	(5.62)	(3.44)
(Increase)/Decrease in other Non Current advances	(6.43)	(2.70)
(Increase)/Decrease in Current Assets, Loans & advances and Other non-current assets	14.80	(206.87)
(Increase)/Decrease in other Current Assets	27.97	(14.21)
Increase/(Decrease) in Trade payables	23.42	(11.10)
Increase/(Decrease) in Provisions	4.20	5.50
Increase/(Decrease) in other Current and non current Liabilities	0.00	0.70
Increase/(Decrease) in Other financial liabilities	7.38	4.37
CASH GENERATED FROM OPERATIONS	36.81	55.53
Taxes Paid (net of refunds)	-	-
NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)	36.81	55.53
B CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property , plant and equipment	(19.86)	(9.42)
Purchase of Intangible assets	(0.13)	(0.50)
Interest Received	22.37	13.18
NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)	2.38	3.26
C CASH FLOWS FROM FINANCING ACTIVITIES		
Repayment of long term borrowings	5.77	5.15
Principal payment of Lease Liability	(34.95)	(31.83)
Interest paid on lease liabilities	(10.97)	(14.23)
Interest paid	(8.47)	(7.58)
NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)	(48.62)	(48.49)
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(9.43)	10.30
Add:Cash and Cash Equivalents at the beginning of the year	56.66	135.44
Cash and Cash Equivalents at the end of the year	47.23	145.74
Components of cash and cash equivalents comprise:		
Cash in hand	12.30	23.70
Balances with banks:		
-In Current Accounts	34.92	121.99
-In Escrow Account	0.02	0.05
Cash and Cash Equivalents in cash flow statement	47.23	145.74

Note:

- 1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
- 2) The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7
- 3)The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED


 NKunj Munge
 Executive Director
 DIN. 08489442
 Place : Mumbai
 Date : 11.11.2023

